Wide complex tachycardia resident survival guide: Difference between revisions
Rim Halaby (talk | contribs) |
m (Bot: Removing from Primary care) |
||
(16 intermediate revisions by one other user not shown) | |||
Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
[[Wide complex tachycardia]] is characterized by a [[heart rate]] more than 100 beats per minute associated with a [[QRS interval]] of more than 120 ms. When [[wide complex tachycardia]] is present, it is important to determine whether the [[tachycardia]] is | [[Wide complex tachycardia]] is characterized by a [[heart rate]] more than 100 beats per minute associated with a [[QRS interval]] of more than 120 ms. When [[wide complex tachycardia]] is present, it is important to determine whether the [[tachycardia]] is [[ventricular tachycardia]] or [[supraventricular tachycardia]] with aberrancy. The diagnosis of [[wide complex tachycardia]] is very challenging as there is no fixed criteria to accurately determine the cause and type of the [[wide complex tachycardia]]. Hemodynamically unstable patients should receive urgent synchronized cardioversion unless the patient has polymorphic [[ventricular tachycardia]] for which unsynchronized cardioversion should be performed. If the [[QRS complex]] and the [[T wave]] can't be distinguished in unstable patients, then the patient should receive unsynchronized cardioversion.<ref name="pmid14563598">{{cite journal| author=Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref> | ||
==Causes== | ==Causes== | ||
Line 23: | Line 23: | ||
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.<ref name="pmid14563598">{{cite journal| author=Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref><ref name="circ.ahajournals.org">{{Cite web | last = | first = | title = Part 7.3: Management of Symptomatic Bradycardia and Tachycardia | url = http://circ.ahajournals.org/content/112/24_suppl/IV-67.full | publisher = | date = | accessdate = 2 March 2014 }}</ref> | A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.<ref name="pmid14563598">{{cite journal| author=Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref><ref name="circ.ahajournals.org">{{Cite web | last = | first = | title = Part 7.3: Management of Symptomatic Bradycardia and Tachycardia | url = http://circ.ahajournals.org/content/112/24_suppl/IV-67.full | publisher = | date = | accessdate = 2 March 2014 }}</ref> | ||
<span style="font-size:85%">Boxes in | <span style="font-size:85%">Boxes in red signify that an urgent management is needed.</span> | ||
{{Family tree/start}} | {{Family tree/start}} | ||
Line 207: | Line 207: | ||
:❑ [[Mottling]] | :❑ [[Mottling]] | ||
:❑ [[Altered mental status]] | :❑ [[Altered mental status]] | ||
❑ [[Chest | ❑ [[Chest discomfort]] suggestive of [[ischemia]] <br> | ||
❑ [[Heart failure|Decompensated heart failure]]</div>}} | ❑ [[Heart failure|Decompensated heart failure]]</div>}} | ||
{{familytree | | |,|-|-|^|-|-|-|.| | | | | | | | | | | |}} | {{familytree | | |,|-|-|^|-|-|-|.| | | | | | | | | | | |}} | ||
{{familytree | | B01 | | | | | B02 | | | | | | | | | | |B01=<div style="float: left; text-align: left; background: #FA8072; width: 16em; padding:1em;"> {{fontcolor|#F8F8FF| '''Yes'''}} </div>|B02=<div style="text-align: center; background: #FFFFFF; width: em; height: px;"> '''No'''</div>}} | {{familytree | | B01 | | | | | B02 | | | | | | | | | | |B01=<div style="float: left; text-align: left; background: #FA8072; width: 16em; padding:1em;"> {{fontcolor|#F8F8FF| '''Yes'''}} </div>|B02=<div style="text-align: center; background: #FFFFFF; width: em; height: px;"> '''No'''</div>}} | ||
{{familytree | | |!| | | | | | |!| | | | | | | }} | {{familytree | | |!| | | | | | |!| | | | | | | }} | ||
{{familytree | | |!| | | | | | A02 | | | | | |A02=<div style="float: left; background: #FFFFFF; text-align: left; width: 15em; padding:1em;"> '''Begin initial management''' <br> ❑ Assess and | {{familytree | | |!| | | | | | A02 | | | | | |A02=<div style="float: left; background: #FFFFFF; text-align: left; width: 15em; padding:1em;"> '''Begin initial management''' <br> ❑ Assess and support circulation, airway, and breathing as needed <br> | ||
❑ Give [[oxygen]] <br> | ❑ Give [[oxygen]] <br> | ||
❑ Monitor [[ECG]], [[blood pressure]], [[oximetry]] <br> | ❑ Monitor [[ECG]], [[blood pressure]], [[oximetry]] <br> | ||
Line 218: | Line 218: | ||
❑ Identify and treat reversible causes </div>}} | ❑ Identify and treat reversible causes </div>}} | ||
{{familytree | | |!| | | | | | |!| | | | | | | | | | | |}} | {{familytree | | |!| | | | | | |!| | | | | | | | | | | |}} | ||
{{familytree | | C01 | | | | | C02 | | | | | | | | | | |C01= <div style="float: left; text-align: left; background: #FA8072; width: 16em; padding:1em;"> {{fontcolor|#F8F8FF| '''Proceed with [[cardioversion|<span style="color:white;">cardioversion </span>]]''' <br>[[Wide complex tachycardia resident survival guide#FIRE: Focused Initial Rapid Evaluation|<span style="color:white;">Check the FIRE | {{familytree | | C01 | | | | | C02 | | | | | | | | | | |C01= <div style="float: left; text-align: left; background: #FA8072; width: 16em; padding:1em;"> {{fontcolor|#F8F8FF| '''Proceed with [[cardioversion|<span style="color:white;">cardioversion </span>]]''' <br>[[Wide complex tachycardia resident survival guide#FIRE: Focused Initial Rapid Evaluation|<span style="color:white;">Check the FIRE algorithm above for the type of cardioversion</span>]]}} </div>|C02= '''Determine the type of arrhythmia''' }} | ||
{{familytree | |,|-|-|-|v|-|-|-|^|-|-|-| | {{familytree | |,|-|-|-|v|-|-|-|^|-|-|-|v|-|-|-|.| |}} | ||
{{familytree | D01 | | D02 | | D03 | | D04 | | D05| | D01= <div style="float: left; text-align: left; width: 15em; padding:1em;"> '''[[Ventricular tachycardia]] or wide QRS tachycardia of unknown origin''' </div>| D02= <div style="float: left; text-align: left; width: 15em; padding:1em;"> '''Wide QRS tachycardia of unknown origin + poor [[LV]] function''' </div>| D03= <div style="float: left; text-align: left; width: 15em; padding:1em;"> ''' Recurrent | {{familytree | D01 | | D02 | | D03 | | D04 | | D05| | D06 | D01= <div style="float: left; text-align: left; width: 15em; padding:1em;"> '''[[Ventricular tachycardia]] or wide QRS tachycardia of unknown origin''' </div>| D02= <div style="float: left; text-align: left; width: 15em; padding:1em;"> '''Wide QRS tachycardia of unknown origin + poor [[LV]] function''' </div>| D03= <div style="float: left; text-align: left; width: 15em; padding:1em;"> ''' Recurrent polymorphic VT''' </div>|D04= <div style="float: left; text-align: left; width: 15em; padding:1em;">'''[[SVT]] + [[BBB]]'''</div>| D05= <div style="float: left; text-align: left; width: 15em; padding:1em;">'''[[SVT]] + [[Preexcitation]]''' </div>|D06= <div style="float: left; text-align: left; width: 15em; padding:1em;">'''[[Atrial fibrillation]] + [[Preexcitation]]''' </div>}} | ||
{{familytree | |!| | | |!| | | |!| | | |!| | }} | {{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | }} | ||
{{familytree | E01 | | E02 | | E03 | | E04 | | E05 | |E01=<div style="float: left; text-align: left; width: 15em; padding:1em;"> Consider one of the following:<ref name="pmid14563598">{{cite journal| auth =Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a rep t of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collab ation with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch. g/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref> <br> | {{familytree | E01 | | E02 | | E03 | | E04 | | E05 | | E06 | |E01=<div style="float: left; text-align: left; width: 15em; padding:1em;"> Consider one of the following:<ref name="pmid14563598">{{cite journal| auth =Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a rep t of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collab ation with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch. g/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref> <br> | ||
❑ '''[[Procainamide]]''' <BR> | ❑ '''[[Procainamide]]''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR> | ||
:❑ Administer 20-50 mg/min IV until arrhythmia suppressed, hypotension ensues, QRS duration increase by 50 %, or maximum dose of 17 mg/kg is given | :❑ Administer 20-50 mg/min IV until arrhythmia suppressed, hypotension ensues, QRS duration increase by 50 %, or maximum dose of 17 mg/kg is given | ||
:❑ Maintenance infusion: 1-4 mg/min | :❑ Maintenance infusion: 1-4 mg/min | ||
<BR>❑ '''[[Sotalol]]''' 100 mg (1.5 mg/kg) IV over 5 minutes <br> | <BR>❑ '''[[Sotalol]]''' 100 mg (1.5 mg/kg) IV over 5 minutes ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<br> | ||
<BR>❑ '''[[Amiodarone]]''' <BR> | <BR>❑ '''[[Amiodarone]]''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR> | ||
:❑ Administer amiodarone 150 mg IV over 10 min | :❑ Administer amiodarone 150 mg IV over 10 min | ||
:❑ Repeat amiodarone as needed for a maximal dose of 2.2g/24h | :❑ Repeat amiodarone as needed for a maximal dose of 2.2g/24h | ||
<BR>❑ '''[[Cardioversion]]''' <BR> <BR>❑ '''[[Lidocaine]]''' <BR> <BR>❑ '''[[Adenosine]]''' <BR> <BR>❑ '''[[Beta blocker]]''' <BR> <BR>❑ '''[[Verapamil]]''' </div> | <BR>❑ '''[[Cardioversion]]''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR> <BR>❑ '''[[Lidocaine]]''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence B]])<BR> <BR>❑ '''[[Adenosine]]''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence C]])<BR> <BR>❑ '''[[Beta blocker]]''' ([[ACC AHA guidelines classification scheme|Class III, level of evidence C]])<BR> <BR>❑ '''[[Verapamil]]''' ([[ACC AHA guidelines classification scheme|Class III, level of evidence B]])</div> | ||
|E02=<div style="float: left; text-align: left; width: 15em; padding:1em;"> Consider one of the following:<ref name="pmid14563598">{{cite journal| auth =Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a rep t of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collab ation with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch. g/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref><br> | |E02=<div style="float: left; text-align: left; width: 15em; padding:1em;"> Consider one of the following:<ref name="pmid14563598">{{cite journal| auth =Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a rep t of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collab ation with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch. g/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref><br> | ||
❑ '''[[Amiodarone]]''' <BR> <BR>❑ '''[[Cardioversion]]''' </div> | ❑ '''[[Amiodarone]]''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR> <BR>❑ '''[[Cardioversion]]''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])</div> | ||
|E03=<div style="float: left; text-align: left; width: 15em; padding:1em;"> | |E03=<div style="float: left; text-align: left; width: 15em; padding:1em;"> | ||
❑ [[Torsade de pointes]] (polymorphic VT associated with long QT syndrome) | ❑ [[Torsade de pointes]] (polymorphic VT associated with long QT syndrome) | ||
:❑ '''[[Magnesium]]''' 1-2 g over 5-60 min, then infusion<ref name=" | :❑ '''[[Magnesium]]''' 1-2 g over 5-60 min, then infusion<ref name="part8">{{Cite web | last = | first = | title = Part 8: Adult Advanced Cardiovascular Life Support | url = http://circ.ahajournals.org/content/122/18_suppl_3/S729.full | publisher = | date = | accessdate = 25 April 2014 }}</ref><br><br> | ||
❑ Polymorphic VT associated with familial long QT syndrome | ❑ Polymorphic VT associated with familial long QT syndrome | ||
:❑ '''[[Magnesium]]''', pacing and/or [[beta blocker]]s<ref name=" | :❑ '''[[Magnesium]]''', pacing and/or [[beta blocker]]s<ref name="part8">{{Cite web | last = | first = | title = Part 8: Adult Advanced Cardiovascular Life Support | url = http://circ.ahajournals.org/content/122/18_suppl_3/S729.full | publisher = | date = | accessdate = 25 April 2014 }}</ref><br><br> | ||
❑ Polymorphic VT associated with myocardial ischemia: | ❑ Polymorphic VT associated with myocardial ischemia: | ||
:❑ '''[[Amiodarone]]''' and '''[[beta blockers]]'''<ref name=" | :❑ '''[[Amiodarone]]''' and '''[[beta blockers]]'''<ref name="part8">{{Cite web | last = | first = | title = Part 8: Adult Advanced Cardiovascular Life Support | url = http://circ.ahajournals.org/content/122/18_suppl_3/S729.full | publisher = | date = | accessdate = 25 April 2014 }}</ref></div> | ||
|E04=<div style="float: left; text-align: left; width: 15em; padding:1em;">Administer one of the following:<ref name="pmid14563598">{{cite journal| auth =Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a rep t of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collab ation with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch. g/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref><br> | |E04=<div style="float: left; text-align: left; width: 15em; padding:1em;">Administer one of the following:<ref name="pmid14563598">{{cite journal| auth =Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a rep t of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collab ation with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch. g/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref><br> | ||
❑ '''[[Vagal maneuvers]]''' <BR> <BR>❑ '''[[Adenosine]]''' <BR> <BR> ❑ '''[[Verapamil]]''' <BR> <BR>❑ '''[[Diltiazem]]''' <BR> <BR>❑ '''[[Beta blocker]]''' <BR> <BR>❑ '''[[Amiodarone]]''' <BR> <BR>❑ '''[[Digoxin]]''' </div> | ❑ '''[[Vagal maneuvers]]''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR> <BR>❑ '''[[Adenosine]]''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence A]])<BR> <BR> ❑ '''[[Verapamil]]''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence A]])<BR> <BR>❑ '''[[Diltiazem]]''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence A]])<BR> <BR>❑ '''[[Beta blocker]]''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence C]])<BR> <BR>❑ '''[[Amiodarone]]''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence C]])<BR> <BR>❑ '''[[Digoxin]]''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence C]])</div> | ||
|E05=<div style="float: left; text-align: left; width: 15em; padding:1em;"> | |E05=<div style="float: left; text-align: left; width: 15em; padding:1em;"> | ||
<span style="font-size:100%;color:red"> '''Avoid the use of AV node blocking agents such as digoxin, calcium channel blockers, beta blockers and adenosine.'''</span><br><br> | <span style="font-size:100%;color:red"> '''Avoid the use of AV node blocking agents such as digoxin, calcium channel blockers, beta blockers and adenosine.'''</span><br><br> | ||
Consider one of the following: | Consider one of the following:<ref name="pmid14563598">{{cite journal| auth =Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a rep t of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collab ation with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch. g/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref><br> | ||
❑ '''[[Procainamide]]''' 100 mg [[infusion]] diluted to 100mg/ml at a rate of 25-50 mg/min every 5 minutes ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]]) <br> | |||
:❑ Administer until the [[arrhythmia]] is suppressed or until 500 mg has been administered<br> | :❑ Administer until the [[arrhythmia]] is suppressed or until 500 mg has been administered<br> | ||
:❑ Wait 10 minutes or longer to administer new [[dosage]] | :❑ Wait 10 minutes or longer to administer new [[dosage]] | ||
<br>❑ '''[[Ibutilide]]''' 1 mg IV [[infusion]] over 10 minutes | <br>❑ '''[[Ibutilide]]''' 1 mg IV [[infusion]] over 10 minutes ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]]) <br> | ||
:❑ Repeat the [[dosage]] if the [[tachycardia]] continues <br> | :❑ Repeat the [[dosage]] if the [[tachycardia]] continues <br> | ||
<br> | <br> | ||
❑ '''[[Flecainide]]''' 50 mg every 12 hours <ref name="pmid23545139">{{cite journal| auth =American College of Cardiology Foundation. American Heart Association. European Society of Cardiology. Heart Rhythm Society. Wann LS, Curtis AB et al.| title=Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a rep t of the American College of Cardiology/American Heart Association Task Force on practice guidelines. | journal=Circulation | year= 2013 | volume= 127 | issue= 18 | pages= 1916-26 | pmid=23545139 | doi=10.1161/CIR.0b013e318290826d | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch. g/cite&retmode=ref&cmd=prlinks&id=23545139 }} </ref> | ❑ '''[[Flecainide]]''' 50 mg every 12 hours ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]]) | ||
:❑ Increase 50mg BID every four days until efficacy is achieved <br> | |||
:❑ Maximum [[dose]] recommended for [[SVT]] is 300 mg/day<br> | |||
<br> | |||
❑ '''[[Cardioversion|DC cardioversion]]''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])</div> | |||
|E06= <div style="float: left; text-align: left; width: 15em; padding:1em;"> | |||
<span style="font-size:100%;color:red"> '''Avoid the use of AV node blocking agents such as digoxin, calcium channel blockers, beta blockers and adenosine.'''</span><br><br> | |||
Consider one of the following:<ref name="pmid23545139">{{cite journal| auth =American College of Cardiology Foundation. American Heart Association. European Society of Cardiology. Heart Rhythm Society. Wann LS, Curtis AB et al.| title=Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a rep t of the American College of Cardiology/American Heart Association Task Force on practice guidelines. | journal=Circulation | year= 2013 | volume= 127 | issue= 18 | pages= 1916-26 | pmid=23545139 | doi=10.1161/CIR.0b013e318290826d | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch. g/cite&retmode=ref&cmd=prlinks&id=23545139 }} </ref><br> | |||
❑ '''[[Procainamide]]''' 100 mg [[infusion]] diluted to 100mg/ml at a rate of 25-50 mg/min every 5 minutes<br> | |||
:❑ Administer until the [[arrhythmia]] is suppressed or until 500 mg has been administered<br> | |||
:❑ Wait 10 minutes or longer to administer new [[dosage]] | |||
<br>❑ '''[[Ibutilide]]''' 1 mg IV [[infusion]] over 10 minutes<br> | |||
:❑ Repeat the [[dosage]] if the [[tachycardia]] continues <br> | |||
<br> | |||
❑ '''[[Flecainide]]''' 50 mg every 12 hours | |||
:❑ Increase 50mg BID every four days until efficacy is achieved <br> | :❑ Increase 50mg BID every four days until efficacy is achieved <br> | ||
:❑ Maximum [[dose]] recommended for [[SVT]] is 300 mg/day<br> | :❑ Maximum [[dose]] recommended for [[SVT]] is 300 mg/day<br> | ||
</div>}} | </div>}} | ||
{{Family tree/end}} | {{Family tree/end}} | ||
==Do's== | ==Do's== | ||
Line 305: | Line 290: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
</div> | |||
[[Category:Disease]] | [[Category:Disease]] | ||
Line 310: | Line 298: | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Resident survival guide]] | [[Category:Resident survival guide]] | ||
Latest revision as of 00:45, 30 July 2020
Wide Complex Tachycardia Resident Survival Guide Microchapters |
---|
Overview |
Causes |
FIRE |
Diagnosis |
Treatment |
Do's |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]; Amr Marawan, M.D. [3]
Overview
Wide complex tachycardia is characterized by a heart rate more than 100 beats per minute associated with a QRS interval of more than 120 ms. When wide complex tachycardia is present, it is important to determine whether the tachycardia is ventricular tachycardia or supraventricular tachycardia with aberrancy. The diagnosis of wide complex tachycardia is very challenging as there is no fixed criteria to accurately determine the cause and type of the wide complex tachycardia. Hemodynamically unstable patients should receive urgent synchronized cardioversion unless the patient has polymorphic ventricular tachycardia for which unsynchronized cardioversion should be performed. If the QRS complex and the T wave can't be distinguished in unstable patients, then the patient should receive unsynchronized cardioversion.[1]
Causes
Life Threatening Causes
Wide complex tachycardia may be a life-threatening condition and must be treated as such irrespective of the underlying cause.
Common Causes
- Atrial fibrillation with aberrancy
- Atrial fibrillation with pre-excitation
- Supraventricular tachycardia (SVT) with aberrancy
- Ventricular tachycardia
Click here for the complete list of causes.
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.[1][2]
Boxes in red signify that an urgent management is needed.
Identify cardinal findings that increase the pretest probability of wide complex tachycardia ❑ Palpitations ❑ QRS complex > 120 ms ❑ Heart rate > 150 beats/min | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient have any of the following findings that require urgent cardioversion? ❑ Hemodynamic instability ❑ Chest discomfort suggestive of ischemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceed with immediate cardioversion Perform the following without delaying cardioversion ❑ Maintain patent airway; assist breathing as necessary ❑ Administer oxygen (if the patient is hypoxemic) ❑ Monitor the cardiac rhythm ❑ Monitor blood pressure and oximetry ❑ Administer IV sedation if the patient is conscious | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
What is the type of arrhythmia? | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
VT/VF presenting as cardiac arrest | Polymorphic VT or undetermined rhythm | Atrial fibrillation with aberrancy | Atrial flutter and other SVTs with aberrancy | Monomorphic VT (regular form and rate) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsynchronized cardioversion ❑ Immediately deliver high-energy unsynchronized shocks | Synchronized cardioversion ❑ Provide an initial dose of biphasic cardioversion of 120-200 Joules (Class IIa, level of evidence A) | Synchronized cardioversion ❑ Provide an initial dose of biphasic cardioversion of 50-100 Joules (Class IIa, level of evidence B) | Synchronized cardioversion ❑ Provide an initial dose of biphasic cardioversion of 100 Joules (Class IIb, level of evidence C) ❑ If the initial shock fails, increase the dose in a stepwise fashion | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Complete Diagnostic Approach
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[1][2]
Abbreviations: Afib: Atrial fibrillation; AP: Accessory pathway; AT: Atrial tachycardia; AVRT: Atrioventricular reentrant tachycardia; BPM: Beat per minute; ECG: Electrocardiogram; ICD: Implantable cardioverter defibrillator; LBBB: Left bundle branch block; RBBB: Right bundle branch block; S1: First heart sound; SVT: Supraventricular tachycardia; SR: Sinus rhythm; VT: Ventricular tachycardia; VF: Ventricular fibrillation
Characterize the symptoms: ❑ Palpitations
❑ Duration
Inquire about the use of proarrhythmic drugs: | |||||||||||||||||||||||||||||||||||||||||||||||||||
Identify possible triggers: | |||||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient:
Neck
Extremities
❑ Palpation ❑ Auscultation
Neurologic | |||||||||||||||||||||||||||||||||||||||||||||||||||
Order labs and tests: ❑ Order and monitor the ECG Perform urgent cardioversion in unstable patients
❑ Invasive electrophysiological studies ❑ Plasma concentration of drugs (eg, digoxin, quinidine or procainamide) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Wide QRS complex tachycardia (QRS duration greater than 120 ms) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Is the rhythm regular? | |||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Atrial fibrillation ❑ Atrial flutter / atrial tachycardia with variable conduction and:
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Is there a 1 to 1 atrium to ventricle relationship? | |||||||||||||||||||||||||||||||||||||||||||||||||||
Yes or unknown | No | ||||||||||||||||||||||||||||||||||||||||||||||||||
QRS morphology in precordial leads | Ventricular rate faster than atrial rate | Atrial rate faster than ventricular rate | |||||||||||||||||||||||||||||||||||||||||||||||||
If the patient shows typical RBBB or LBBB | Precordial leads: ❑ Concordant ❑ No R/S pattern ❑ Onset of R to nadir longer than 100ms | RBBB pattern: ❑ qR, Rs or Rr' in V1 ❑ Frontal plane axis range from +90 degrees to -90 degrees | LBBB pattern: ❑ R in V1 longer than 30 ms ❑ R to nadir of S in V1 greater than 60 ms ❑ qR or qS in V6 | VT | ❑ Atrial tachycardia ❑ Atrial flutter | ||||||||||||||||||||||||||||||||||||||||||||||
SVT | VT | VT | VT | ||||||||||||||||||||||||||||||||||||||||||||||||
Differentiating SVT from VT
Shown below is a table summarizing some clues that help differentiate SVT from VT.[1]
Clues | Type of arrhythmia |
Irregularly irregular rhythm | Atrial fibrillation or atrial flutter with aberrancy |
Previous myocardial infarction or structural heart disease | Ventricular tachycardia |
Ventricular rate faster than atrial rate | Ventricular tachycardia |
Typical RBBB or LBBB | Supraventricular tachycardia |
Precordial leads: ❑ Concordant ❑ No R/S pattern ❑ Onset of R to nadir longer than 100ms |
Ventricular tachycardia |
RBBB pattern: ❑ qR, Rs or Rr' in V1 ❑ Frontal plane axis range from +90 degrees to -90 degrees |
Ventricular tachycardia |
LBBB pattern: ❑ R in V1 longer than 30 ms ❑ R to nadir of S in V1 greater than 60 ms ❑ qR or qS in V6 |
Ventricular tachycardia |
For more details about differentiating VT from SVT, click here
Treatment
Shown below is an algorithm depicting the treatment of wide complex tachycardia.[1][2][3]
Afib: Atrial fibrillation; BBB: Bundle branch block; CAB: Circulation, airway and breathing; LV: Left ventricle; SVT: Supraventricular tachycardia; VT: Ventricular tachycardia; WPW: Wolff Parkinson White
Does the patient have any of the following findings that require urgent cardioversion? ❑ Hemodynamic instability ❑ Chest discomfort suggestive of ischemia | |||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||
Begin initial management ❑ Assess and support circulation, airway, and breathing as needed ❑ Give oxygen | |||||||||||||||||||||||||||||||||||||||||||||||
Determine the type of arrhythmia | |||||||||||||||||||||||||||||||||||||||||||||||
Ventricular tachycardia or wide QRS tachycardia of unknown origin | Wide QRS tachycardia of unknown origin + poor LV function | Recurrent polymorphic VT | |||||||||||||||||||||||||||||||||||||||||||||
Consider one of the following:[1] ❑ Procainamide (Class I, level of evidence B)
❑ Cardioversion (Class I, level of evidence B) ❑ Lidocaine (Class IIb, level of evidence B) ❑ Adenosine (Class IIb, level of evidence C) ❑ Beta blocker (Class III, level of evidence C) ❑ Verapamil (Class III, level of evidence B) | Consider one of the following:[1] ❑ Amiodarone (Class I, level of evidence B) ❑ Cardioversion (Class I, level of evidence B) | ❑ Torsade de pointes (polymorphic VT associated with long QT syndrome) ❑ Polymorphic VT associated with familial long QT syndrome
❑ Polymorphic VT associated with myocardial ischemia:
| Administer one of the following:[1] ❑ Vagal maneuvers (Class I, level of evidence B) ❑ Adenosine (Class I, level of evidence A) ❑ Verapamil (Class I, level of evidence A) ❑ Diltiazem (Class I, level of evidence A) ❑ Beta blocker (Class IIb, level of evidence C) ❑ Amiodarone (Class IIb, level of evidence C) ❑ Digoxin (Class IIb, level of evidence C) | Avoid the use of AV node blocking agents such as digoxin, calcium channel blockers, beta blockers and adenosine.
| Avoid the use of AV node blocking agents such as digoxin, calcium channel blockers, beta blockers and adenosine.
| ||||||||||||||||||||||||||||||||||||||||||
Do's
- Use high energy unsynchronized cardioversion immediately if you aren't sure of the type of arrhythmia.
- Monitor the patient all the time as he might be unstable or pulseless at anytime.
- Consider adenosine as a safe and potentially effective therapy in the initial management of stable undifferentiated regular monomorphic wide complex tachycardia.[2]
- Refer the patient to an arrhythmia specialist when the tachycardia causes syncope or dyspnea as well as when the wide complex tachycardia is of unknown cause.[1]
- Place an ambulatory 24 hour Holter when the tachycardia is frequent and transient.[1]
- Treat the patient as having a ventricular tachycardia when the diagnosis of supraventricular tachycardia can not be made.[1]
- Suspect ventricular tachycardia in a patient with wide complex tachycardia and previous myocardial infarction or a history of structural heart disease.[1]
- Use beta blockers with caution in pulmonary diseases or congestive heart failure.
- Balance the use of IV analgesics or sedatives with the risk of further hemodynamic deterioration.
- Consider rate control with either diltiazem or beta blockers for patients with atrial fibrillation with aberrancy. An expert consultation is advised.
Don'ts
- Don't rely on the hemodynamic status of the patient and the heart rate to differenciate SVT from VT and this might lead to inappropriate dangerous therapy.
- Don't delay cardioversion to sedate or to establish an IV line to the patient.
- Don't adminster verapamil for wide complex tachycardia unless the wide complex tachycardia is known to be of supraventricular origin.[2]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ; et al. (2003). "ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society". J Am Coll Cardiol. 42 (8): 1493–531. PMID 14563598.
- ↑ 2.0 2.1 2.2 2.3 2.4 "Part 7.3: Management of Symptomatic Bradycardia and Tachycardia". Retrieved 2 March 2014.
- ↑ 3.0 3.1 g/cite&retmode=ref&cmd=prlinks&id=23545139 "Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a rep t of the American College of Cardiology/American Heart Association Task Force on practice guidelines" Check
|url=
value (help). Circulation. 127 (18): 1916–26. 2013. doi:10.1161/CIR.0b013e318290826d. PMID 23545139. Unknown parameter|auth=
ignored (help) - ↑ 4.0 4.1 4.2 "Part 8: Adult Advanced Cardiovascular Life Support". Retrieved 25 April 2014.